发布时间：2008.

价格：

Paper copy: 1000 EUR

PDF (1-5 users): 1500 EUR

PDF corporate license: 3000 EUR

摘要

 
The market for home wireless monitoring in healthcare is still nascent, but rapidly evolving. Among the most common conditions to monitor at home are irregular heartbeats or cardiac arrhythmia, high blood pressure, the glucose levels in diabetes, and high levels of lipids or fats in the blood. In Europe and North America 40 million people have cardiac arrhythmia, 200 million people have high blood pressure, 60 million people are diabetic, and 180 million people have severe elevation of blood lipids. All these diseases are increasing as a result of people getting older and heavier, and all are major causes of high healthcare costs. Today, there exists equipment allowing home monitoring of all the conditions. Almost all new devices
are digital, and there is a strong tendency towards data transfer capability and wireless
features. While many companies are making efforts towards developing specialised PDAs coupled to each monitor, Berg Insight believes that other devices as mobile phones and computers will be used, and that data will be collected in central server systems, allowing location-independent access. Furthermore, Internet based health portals will drive the development. Berg Insight expects data monitoring and distance disease management to become the key parts of tomorrow’s healthcare system.
 
The market for wireless monitoring solutions for home medical care is still in a very early healthcare industry, which is thoroughly regulated and generally operates under difficult financial conditions. Currently remote monitoring has only given rise to a substantial market in cardiac monitoring.
 
The global market for cardiac monitoring is worth less than US$ 300 million, mainly in the US. There is currently an ongoing shift in technology from primitive transtelephonic transfer to modern means of communication. The market is dominated by CardioNet, CardGuard and Raytel Cardiac Services, but there are also several upstart companies such as Transoma offering interesting alternatives, as well as established medical device manufacturers such as Medtronic. The blood pressure monitoring world market is worth about US$ 800 million, with a growth rate of 9 percent, and dominated by Omron, with Microlife and A&D Medical as runners up. The adoption of wireless solutions is still in its infancy in this segment. The world glucose level monitoring market is worth US$ 8.9 billion, and is growing at a rate of 11 percent annually. Roche, Johnson & Johnson, Abbott and Bayer together hold 90 percent of the market. Abbott recently became the first of the major companies to offer continuous glucose monitoring. The global lipid monitoring market is worth  approximately US$ 100
million and is growing by 7 percent annually. Biomedix and CardioChek are the market
leaders.
 
Recently, a range of IT and telecom companies, such as France Telecom, Deutche Telekom and Alcaltel-Lucent have released healthcare related products, and Qualomm even plans to start a health-oriented MVNO, Lifecomm. Also, many handset manufacturers have shown a clear interest in health-related applications, and some, like LG, have even integrated medical monitors in certain models. Furthermore the IT giants Google and Microsoft have recently released health portals, where users can gather and analyse medical data.

目录及图表

Table of Contents.........................................................................................................................i
List of Figures..............................................................................................................................v
Executive summary....................................................................................................1
1  The challenge from welfare diseases...........................................3
1.1  Introduction..................................................................................................................3
1.2  Common chronic welfare diseases.............................................................................4
1.2.1  Cardiac arrhythmia................................................................................................4
1.2.2  Hypertension.........................................................................................................7
1.2.3  Diabetes................................................................................................................7
1.2.4  Hyperlipidemia......................................................................................................8
1.3  Healthcare providers and reimbursement systems by market............9
1.3.1  Healthcare in Europe ..........................................................................................12
1.3.2  Healthcare in the US and Canada ......................................................................13
1.3.3  Healthcare in Asia and Australia.........................................................................14
2  Home healthcare monitoring.............................................................................................17
2.1  Cardiac monitoring....................................................................................................17
2.2  Blood pressure monitoring........................................................................................20
2.3  Glucose monitoring...................................................................................................21
2.4  Lipid monitoring.........................................................................................................24
2.5  Technology trends in health monitoring....................................................................25
2.5.1  Going digital, going wireless...............................................................................25
2.5.2  Dedicated PDAs vs general devices...................................................................27
2.5.3  Outsourcing of health monitoring.......................................................................30
2.5.4  Distance disease management...........................................................................31
2.5.5  Frequency and volume of data to transfer..........................................................32
2.5.6  eHealth and telemedicine ...................................................................................33
2.6  Regulatory environment............................................................................................34
2.6.1  Regulatory environment in Europe.....................................................................34
  Regulatory environment in the US......................................................................35
2.6.2
2.6.3  Regulatory environment on other major markets...............................................37
2.6.4  International standardization...............................................................................37
3  Healthcare monitoring solution providers.........................................................................39
3.1  Cardiac monitoring vendors......................................................................................40
3.1.1  CardioNet............................................................................................................40
3.1.2  Card Guard..........................................................................................................42
3.1.3  Philips Healthcare and Raytel Cardiac Services.................................................44
3.1.4  Aerotel.................................................................................................................44
3.1.5  Kiwok...................................................................................................................45
3.1.6  Medtronic ............................................................................................................45
3.1.7  SHL Telemedicine...............................................................................................46
3.1.8  Transoma Medical...............................................................................................47
3.1.9  T Z Medical..........................................................................................................49
3.2  Blood pressure monitoring vendors..........................................................................49
3.2.1  Omron Healthcare...............................................................................................49
3.2.2  A&D Medical........................................................................................................50
3.2.3  AViTA...................................................................................................................51
3.2.4  Honeywell Hommed............................................................................................51
3.2.5  HoMedics............................................................................................................51
3.2.6  IEM......................................................................................................................52
3.2.7  Microlife...............................................................................................................52
3.2.8  Vitaphone............................................................................................................52
3.3  Glucose level monitoring vendors.............................................................................53
3.3.1  Roche..................................................................................................................53
3.3.2  Johnson & Johnson............................................................................................54
3.3.3  Abbott Laboratories.............................................................................................55
3.3.4  Bayer Healthcare.................................................................................................55
3.3.5  BodyTel...............................................................................................................56
3.3.6  Dexcom...............................................................................................................57
3.3.7  HealthPia America...............................................................................................57
3.3.8  Smith’s Medical...................................................................................................58
3.4  Lipid monitoring vendors...........................................................................................58
3.4.1  CardioChek.........................................................................................................58
3.4.2  Biomedix..............................................................................................................59
3.5  Other companies.......................................................................................................59
3.5.1  Arrowhead Electronic Healthcare.......................................................................59
3.5.2  iMetrikus..............................................................................................................60
3.5.3  RTX Healthcare ...................................................................................................60
3.5.4  Viterion TeleHealthcare.......................................................................................60
3.5.5  T+ Medical..........................................................................................................61
4  Telecom and IT industry initiatives....................................................................................63
4.1  Telecom operators.....................................................................................................63
4.1.1  France Telecom creates Orange Healthcare business unit................................63
4.1.2  Telecom Italia invests in Telbios.........................................................................64
4.1.3  SaskTel first to launch Alcatel-Lucent’s LifeStat .................................................65
4.1.4  Vodafone Spain pilots Aerotel’s e-CliniQ system................................................65
4.1.5  Qualcomm plans Lifecomm health-oriented MVNO...........................................65
4.1.6  Deutsche Telekom’s T-City project.....................................................................66
4.1.7  NTT DoCoMo introduces health-oriented handsets...........................................67
4.2  Handset manufacturers.............................................................................................67
4.2.1  Nokia and Apple to make smartphones health applications platforms?............68
4.2.2  LG Electronics to introduce handset with blood pressure meter.......................68
4.3  IT companies.............................................................................................................69
4.3.1  Google Health.....................................................................................................69
4.3.2  Microsoft HealthVault..........................................................................................70
4.3.3  Intel Health Guide................................................................................................70
4.4  Industry associations.................................................................................................71
4.4.1  Continua Health Alliance.....................................................................................71
4.4.2  The Bluetooth SIG's Medical Working Group.....................................................71
5  Market trends and recommendations...............................................................................73
5.1  Market analysis..........................................................................................................73
5.2  Market drivers and challenges..................................................................................75
5.2.1  An aging population............................................................................................75
  Increasing welfare disease prevalence...............................................................76
5.2.2
5.2.3  Focus on disease prevention..............................................................................76
5.2.4  Risks related to alternative treatments................................................................78
5.3  Potential market catalysts..........................................................................................79
5.3.1  Increased monitoring during clinical trials..........................................................79
5.3.2  Insurance companies demanding monitoring....................................................81
5.3.3  Non-prescribed monitoring.................................................................................82
5.4  Recommendations for mobile industry players.........................................................83
Glossary..........................................................................................85